Late in 2021 the European Commission opened a feedback round on Microsoft’s planned $19.7 billion purchase of Nuance Communications, a speech-recognition and AI firm whose biggest footprint is in medicine. The regulator asked competitors and customers whether combining the two companies would stifle competition in medical AI and transcription products. The request for views was a procedural step after Microsoft formally notified the EU of the transaction, and it preceded a decision on clearing the deal or launching an in-depth Phase II inquiry.
The Commission granted unconditional antitrust clearance on December 21, 2021. The UK’s Competition and Markets Authority followed on March 2, 2022. The US Department of Justice reviewed the deal and chose not to challenge it. The acquisition formally closed on March 4, 2022.
At $19.7 billion including Nuance’s net debt, the transaction was Microsoft’s second-biggest acquisition, trailing only the $26.2 billion LinkedIn purchase in 2016.
The markets the EU scrutinized
The Commission’s request for feedback concentrated on two overlapping markets: medical AI and transcription software. Nuance builds speech recognition for physician documentation. Its Dragon Medical One platform lets hundreds of thousands of doctors dictate notes directly into electronic health record systems. Microsoft was already supplying cloud services to providers through Azure. The worry was that fusing Microsoft’s cloud infrastructure with Nuance’s voice AI for care settings would produce a bundle no rival could match, trapping hospitals with a single vendor for both transcription and cloud computing.
Why tying was on the radar
The EU also examined whether Microsoft could steer users toward Nuance’s products through its control of Windows and Office, though the feedback materials did not single out any precise tying theory. The regulator asked third parties to point to markets where the merged entity would have both the ability and incentive to lock out competitors. No specific objections from rivals or customers surfaced publicly during the consultation window.
The timeline for the EU decision
The Commission set a provisional decision deadline of December 21, 2021, the close of the initial Phase I review. Serious concerns would have triggered a Phase II investigation lasting several more months. The decision to clear the deal unconditionally on that date signaled the watchdog found no competition problems requiring remedies or a deeper probe.
How the consultation unfolded
Feedback collection ran during the weeks leading up to the deadline. The Commission never disclosed the date it opened the window or how many responses arrived. The short timetable reflected one fact: Microsoft and Nuance had already filed in other jurisdictions, so the EU had access to those submissions.
Reviews in the UK and US
The UK’s Competition and Markets Authority launched its own review in 2021 and cleared the transaction on March 2, 2022, two days before it closed. The UK regulator demanded no divestitures or behavioral commitments. The US Department of Justice also completed its review without filing suit.
Facing coordinated questions in three jurisdictions, Microsoft ended up with unconditional approvals across the board. The clean sweep suggests the antitrust theory of harm in medical AI and transcription was weaker than some competitors had hoped. Nuance commanded a sizable share of speech recognition for care providers, but the market remained fragmented and hospital switching costs ran high regardless of the merger.
Microsoft's strategic rationale and Nuance's position
Microsoft had announced the acquisition in April 2021. The public reasoning: Nuance’s AI for medicine would accelerate Microsoft’s push into industry-specific clouds, particularly one serving the health sector. The two companies already maintained a partnership; they had worked together on ambient clinical intelligence, a system that listens to doctor-patient conversations through microphones and auto-generates notes. The acquisition was meant to fuse that integration more deeply.
Nuance's footprint in medical speech recognition
Nuance’s position in medical AI was commanding. Its Dragon Medical platform had been the standard for physician speech recognition for more than a decade. The product line had grown to include AI-powered coding and revenue cycle management. For Microsoft, buying Nuance meant acquiring a distribution channel into hospitals and a proven product instead of building one from scratch. The steep price reflected Nuance’s steady profitability and long-term contracts with major health systems.
Key facts
- Deal value: $19.7 billion including Nuance's net debt
- Announced: April 2021
- EU clearance: December 21, 2021, unconditional
- UK clearance: March 2, 2022
- Deal closed: March 4, 2022
- Microsoft's second-largest acquisition: After LinkedIn ($26.2 billion in 2016)
- Regulators: European Commission, UK CMA, US DOJ
Regulatory timeline
| Jurisdiction | Regulator | Decision date | Outcome |
|---|---|---|---|
| European Union | European Commission | December 21, 2021 | Unconditional clearance |
| United Kingdom | Competition and Markets Authority | March 2, 2022 | Unconditional clearance |
| United States | Department of Justice | Before March 4, 2022 | No challenge |
